This unique book combines a review of the hemp (Cannabis) pest and disease literature published over the past 50 years with up-to-date information on modern biological control techniques. Each pest and disease organism is presented in the same format, covering economic impact, geographical and host-plant range, plant symptoms, taxonomic description, life history, and differential diagnosis. Important cultural, mechanical, biological and chemical controls are highlighted with charts, illustrations and explicit instructions. Easy-to-use keys are included for rapid identification of the most common pests. Introductory chapters describe the general principles of plant protection, requirements for healthy plant growth, and taxonomy of parasites and pathogens. Contents include: principles of plant protection; requirements for growth; classification of organisms associated with Cannabis; insects and mites; fungal diseases; other organisms (including nematodes, viruses, bacteria, protozoa, slugs, vertebrate pests and non-insect arthropods); abiotic diseases; post-harvest problems; cultural and mechanical methods; biological control; biorational chemical control; and a dichotomous key of pests and diseases.

Despite repeated initiatives over the past decade, migraine remains under-recognised, under-diagnosed and under-treated in everyday clinical practice. The Migraine in Primary Care Advisors (MIPCA) group has produced new guidelines for migraine management to attempt to rectify this situation. MIPCA is a group of physicians, nurses, pharmacists and other healthcare professionals dedicated to the improvement of headache management in primary care, who have also worked closely with the Migraine Action Association (the UK patients' group) in the development of these guidelines. The principles of the new MIPCA guidelines are: To arrange specific consultations for headache. To institute a system of detailed history taking, patient education and buy-in at the outset of the consultation. To utilise a new screening algorithm for the differential diagnosis of headache, which can be confirmed by further questioning, if necessary. To institute a process of management that is individualised for each patient, using a new algorithm. Assessing the impact on the patient's daily life is a key aspect of diagnosis and management. To prescribe only treatments that have objective evidence of favourable efficacy and tolerability. To utilise prospective follow-up procedures to monitor the success of treatment. To organise a team approach to headache management in primary care.

◥ HER2 Po ten cy Tucatinib blocks MAPK and PI3K/AKT signaling through inhibition of HER2 kinase activity

Although the effects of highly active antiretroviral therapy (HAART) have resulted in substantial improvements in the systemic health of patients with HIV infection, concerns remain that these medications, which cross the blood-brain barrier poorly, may have a less beneficial effect on nervous system function. This raises the possibility that there may be a progressive long-term decline in neurologic function in patients with adequate systemic response. In a prospective longitudinal study, subjects were evaluated immediately before instituting HAART. Forty-eight subjects underwent ultrasensitive HIV RNA quantitative evaluation of both plasma and cerebrospinal fluid as well as neurologic and neuropsychological examinations. They were reevaluated 6 months after treatment initiation while receiving stable HAART. Both plasma and cerebrospinal fluid viral levels significantly declined after treatment. There was significant improvement in neurologic and neuropsychological functioning after HAART. These results indicate that despite the poor central nervous system penetration of most of these agents, there is satisfactory short-term improvement in both central nervous system viral burden and nervous system function with HAART. However, because treatment failure is increasingly likely over time, continued longitudinal evaluation of this group of subjects is required.